Eton Pharmaceuticals Completes 03 Life Sciences Acquisition
Ticker: ETON · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1710340
Sentiment: neutral
Topics: acquisition, pharmaceuticals, growth
TL;DR
Eton just bought 03 Life Sciences, deal closed Dec 31, 2024. Should make them more money.
AI Summary
Eton Pharmaceuticals, Inc. announced the completion of its acquisition of 100% of the outstanding equity interests in 03 Life Sciences on December 31, 2024. This transaction is expected to be accretive to earnings per share in the first full year following the closing. The company did not disclose the specific purchase price or financial terms of the deal.
Why It Matters
This acquisition signifies Eton Pharmaceuticals' strategic growth and is anticipated to boost its profitability, potentially impacting its stock value and market position.
Risk Assessment
Risk Level: medium — The lack of specific financial details regarding the acquisition, such as the purchase price and debt financing, introduces uncertainty.
Key Numbers
- 100% — Equity Interest Acquired (Eton Pharmaceuticals acquired full ownership of 03 Life Sciences.)
- 1231 — Fiscal Year End (Indicates the end of Eton Pharmaceuticals' financial reporting year.)
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 03 Life Sciences (company) — Acquired entity
- December 31, 2024 (date) — Closing date of acquisition
- Delaware (jurisdiction) — State of incorporation
- Deer Park, Illinois (location) — Principal executive offices
FAQ
What was the purchase price for 03 Life Sciences?
The filing does not disclose the specific purchase price for 100% of the outstanding equity interests in 03 Life Sciences.
When did the acquisition of 03 Life Sciences officially close?
The acquisition of 03 Life Sciences was completed on December 31, 2024.
What is the expected financial impact of this acquisition on Eton Pharmaceuticals?
Eton Pharmaceuticals expects the acquisition to be accretive to earnings per share in the first full year following the closing.
In which state is Eton Pharmaceuticals incorporated?
Eton Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Eton Pharmaceuticals?
The principal executive offices of Eton Pharmaceuticals are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
Filing Stats: 646 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-01-03 07:05:15
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $7.0 million — ement, the Company purchased Galzin for $7.0 million at closing and paid an additional $0.2
- $0.2 million — llion at closing and paid an additional $0.2 million for product inventory. The Company will
Filing Documents
- eton20241219_8k.htm (8-K) — 28KB
- ex_761795.htm (EX-10.1) — 177KB
- ex_759219.htm (EX-99.1) — 21KB
- 0001437749-25-000109.txt ( ) — 404KB
- eton-20241231.xsd (EX-101.SCH) — 3KB
- eton-20241231_def.xml (EX-101.DEF) — 12KB
- eton-20241231_lab.xml (EX-101.LAB) — 15KB
- eton-20241231_pre.xml (EX-101.PRE) — 12KB
- eton20241219_8k_htm.xml (XML) — 3KB
01: Completion of Acquisition or Disposition of Assets
Item 2.01: Completion of Acquisition or Disposition of Assets On December 31, 2024, Eton Pharmaceuticals, Inc. ("Eton" or the "Company") acquired Galzin (zinc acetate) from Teva Pharmaceuticals USA, Inc. ("Teva"). Galzin is the only FDA-approved zinc treatment for the maintenance of patients with Wilson Disease who have been initially treated with a chelating agent. It is estimated that less than 5,000 patients in the United States are currently being treated for Wilson Disease. Eton expects to assume the commercialization of the product in the United States in the first quarter of 2025 with its metabolic sales force supporting healthcare professionals who treat Wilson Disease. As part of the transaction, Eton has also acquired European rights to the product, where it is commercialized under the tradename Wilzin by a third party. Under an existing agreement, Eton will continue to supply the product to the third party and the third party is responsible for all commercialization activities. Under the terms of the purchase agreement, the Company purchased Galzin for $7.0 million at closing and paid an additional $0.2 million for product inventory. The Company will also pay Teva a royalty of 10% of U.S. net sales through the tenth anniversary of the Company's first commercial sale of the product in the U.S. A copy of the asset purchase agreement dated December 31, 2024 and the press release announcing the transaction dated January 3, 2025 are being filed herewith and are numbered in accordance with Item 601 of Regulation S-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 10.1 Asset Purchase Agreement dated December 31, 2024 between Teva Pharmaceuticals USA, Inc. and the Registrant (portions of the Exhibit have been redacted). Exhibit 99.1 Press Release dated January 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 3, 2025 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4